Evaluation of siRNA therapeutic approaches for the regulation of ceramide synthesis

Selected Abstract - SITeCS Congress 2025

Elsa Franchi
Department of Pharmacological and Biomolecular Sciences Rodolfo Paoletti, Università degli Studi di Milano, Milan, Ital
Angelika Witoslawska
Finnish Cardiovascular Research Center, University of Tampere, Tampere, Finland
Alice Colombo
Department of Pharmacological and Biomolecular Sciences Rodolfo Paoletti, Università degli Studi di Milano, Milan, Italy
Stefano Manzini
Department of Pharmacological and Biomolecular Sciences Rodolfo Paoletti, Università degli Studi di Milano, Milan, Italy
Giada Poletti
Department of Pharmacological and Biomolecular Sciences Rodolfo Paoletti, Università degli Studi di Milano, Milan, Italy
Marco Busnelli
Department of Pharmacological and Biomolecular Sciences Rodolfo Paoletti, Università degli Studi di Milano, Milan, Italy
Raymond Schiffelers | Bio
CDL Research, University Medical Center Utrecht, Utrecht, The Netherlands
Michael Hannus | Bio
siTOOLs Biotech GmbH, Planegg, Germany
Richard Sprenger
Department of Biochemistry and Molecular Biology, VILLUM Center for Bioanalytical Sciences, University of Southern Denmark, Odense, Denmark
Christer Ejsing
Department of Biochemistry and Molecular Biology, VILLUM Center for Bioanalytical Sciences, University of Southern Denmark, Odense, Denmark
Reijo Laaksonen
Finnish Cardiovascular Research Center, University of Tampere, Tampere, Finland
Giulia Chiesa
Department of Pharmacological and Biomolecular Sciences Rodolfo Paoletti, Università degli Studi di Milano, Milan, Italy

Abstract

Background and aim. Since increased plasma ceramide levels have recently emerged as a pro-atherogenic factor, selective modulation of hepatic ceramide biosynthesis might represent a novel therapeutic approach to reduce cardiovascular risk.
Methods. The efficacy of siRNA-based treatments (siPOOLs) on ceramide level modulation was tested by targeting single enzymes or couples of enzymes playing key roles in ceramide metabolism. In vitro, the effects of siRNAs on target gene expression and lipidome changes were evaluated in Hepa1c1c7 murine hepatocytes (96 hours after treatment, 6 nM). For in vivo studies, siPOOLs were encapsulated in lipid nanoparticles (LNPs) and first tested for hepatic tropism by confocal microscopy (single intraperitoneal injection of Cy5-labelled LNPs, 2 mg/kg, in C57Bl/6 male mice). In vivo gene silencing efficacy, effects on plasma and liver lipidome, and histological analyses were assessed after four intraperitoneal injections (2 mg/kg every 72 hours) in 8-week-old C57Bl/6 male mice.
Results. In vitro validation identified siRNAs effective in reducing target gene expression and lowering ceramide levels in hepatocytes. Biodistribution studies showed that siRNA-LNPs accumulated primarily in the liver and in the spleen. In vivo testing showed variable silencing efficacy of siRNA-LNPs, ranging from –17% (Sptlc1) to –80% (Sptssa), depending on the target and the combination/dose administered. Despite a promising silencing effect, lipidomic analyses of plasma and liver did not show effective modulation of ceramide levels. Treated mice displayed extramedullary hematopoiesis in the spleen and, in a few cases, hepatic necrosis.
Conclusions. The siRNA-LNP approach resulted in efficient silencing but did not translate into plasma ceramide modulation. A second strategy, consisting of N-acetyl galactosamine-conjugated siRNAs, will be tested in vitro and in vivo, with the aim of achieving higher efficacy and reduced toxicity.

Send mail to Author


Send Cancel

Custom technologies based on your needs